1. Introduction
Alopecia areata is an autoimmune condition in which the body attacks its own hair follicles, characterized by localized or widespread hair loss resulting in round or patchy bald spots [
1]. Alopecia is commonly observed on the scalp but can also affect the eyebrows, eyelashes, and other areas of the body with hair [
2]. Although the estimated global prevalence of approximately 0.1% to 0.2% [
3] represents a relatively small proportion of the population, alopecia areata can affect individuals of all ages, from children to adults [
4,
5]. The disease has a long history, with descriptions dating back to ancient times [
6]. Alopecia has wide-ranging impacts on patients worldwide [
7], significantly affecting psychological well-being and potentially causing anxiety, depression, and issues with self-image [
8]. Additionally, alopecia areata presents a series of challenges on economic and social levels, including medical expenses, limited employment opportunities, and social discrimination [
9]. Therefore, the global impact of alopecia areata needs to be comprehensively considered, encompassing physiological, psychological, and social aspects, to formulate better support and rehabilitation programs that provide comprehensive care and support for patients [
7].
Various treatment methods can be employed based on symptoms and preferences to manage and alleviate the symptoms and improve the quality of life of patients with alopecia areata [
10]. The treatment and research of alopecia areata have been widely discussed [
11]. Common treatment approaches include local and systemic therapies [
12]. Local treatments involve the application of topical medications such as corticosteroid creams, minoxidil, and topical immunomodulators to promote hair regrowth and reduce the affected area [
3]. Conversely, systemic treatment involves the use of oral or injectable medications such as methotrexate and cyclosporine [
13] to suppress abnormal immune responses and is used in patients with severe or extensive conditions [
14]. Other methods, such as phototherapy, laser therapy, and oral supplementation of vitamins, have been attempted in some patients [
15]. In cases of limited or no clinical efficacy of the above treatments, surgical procedures, hair transplantation, and hair follicle cell transplantation may be considered [
15]. The treatment approach for alopecia areata should be tailored by physicians based on the specific circumstances of each patient to achieve optimal therapeutic outcomes [
16]. However, a complete cure for alopecia areata is not yet available. Therefore, further research is needed to help unravel the specific pathogenic mechanisms of alopecia areata and provide a better theoretical basis for the treatment and intervention of this condition.
The molecular mechanisms underlying the development of alopecia areata involve multiple factors [
17]. Current research indicates that both abnormal immune responses and genetic factors play important roles in the pathogenesis [
18]. Immune cells such as T cells and natural killer cells may be activated and release inflammatory cytokines and cytotoxic molecules, resulting in the damage and destruction of hair follicle cells [
19]. Moreover, alopecia areata is often associated with other autoimmune diseases such as thyroid disorders and rheumatoid arthritis [
20]. Genetic factors are believed to play significant roles in the onset of alopecia areata [
21] with certain genetic variations increasing individual susceptibility, often exhibiting familial clustering [
19]. Furthermore, environmental factors and stress can also influence the onset of alopecia areata [
22]. Overall, the molecular mechanisms of alopecia areata appear to involve a complex interplay of abnormal immune responses, genetic factors, and environmental and stress-related factors [
23]. Accordingly, the aim of this study was to identify candidate molecules through RNA-sequencing that may be associated with hair follicle development in lambs and to explore the underlying mechanisms using in vitro and in vivo models.
In this study, we performed multi-omics analyses using lamb models exhibiting different wool phenotypes, including miRNA sequencing, mRNA sequencing, and proteomic sequencing. We identified miR-199a-3p as the sole significantly upregulated small RNA in the skin tissue of fine wool lambs. Further integrated analysis of mRNA and proteomic sequencing revealed that miR-199a-3p possesses the potential to regulate hair follicle development via the PTPRF/β-catenin axis. Thus, we established miRNA injection models in sheep veins and mouse skin to validate the regulatory role of miR-199a-3p in hair follicle development. Surprisingly, miR-199a-3p not only regulates hair follicle development in mice but also in lambs, and these animal models also suggest a potential molecule associated with alopecia areata, which provides potential treatment options.
3. Discussion
In this study, we showed that PTyr142 β-catenin transcription activity could be triggered by the newly identified interaction between
miR-199a-3p and PTPRF using lamb and mouse models in vivo, as well as in vitro functional studies in a human cell line. At the cellular level, the elevated expression of
miR-199a-3p inhibits the translation of its target gene
PTPRF, subsequently causing the translocation of β-catenin into the cell nucleus and activation of the Wnt-signaling pathway. Conversely, when the expression of
miR-199a-3p is suppressed, the activity of the Wnt-signaling pathway is inhibited. At the in vivo level in lambs and mice, we demonstrate that
miR-199a-3p regulates wool and mouse hair development by targeting the PTPRF/β-catenin axis. Furthermore, in vivo experiments in mice resulted in differential expression of a series of alopecia-related marker genes, including several immune response-signaling genes (
Figure 1F and
Figure 6E,F). Aberrant immune responses are considered a major cause of alopecia areata, and interleukin-15 is considered a key factor in the development of the condition [
32,
33]. Therefore, we propose a hypothesis that
miR-199a-3p may exhibit a similar regulatory mechanism in wool follicle development as observed in the pathogenesis of alopecia areata.
β-catenin phosphorylation at Tyr142 is reported to facilitate the release of β-catenin from the cell membrane and its translocation to the nucleus [
25]. Further, when tyrosine kinase (c-Met) is activated by hepatocyte growth factor/serum ferritin [
26], the β-catenin/E-cadherin complex is disintegrated, and β-catenin enters the cytoplasm from the cell membrane; β-catenin then enters the nucleus with the help of BCL9-2 (a protein homologous to Drosophila Legless) [
34]. However, mutant β-catenin phosphorylated at Tyr142 cannot bind to BCL9-2 [
35] and loses its ability to enter the nucleus, resulting in significantly decreased transcriptional activity [
26]. Similar studies have shown that when c-Met is mutated, β-catenin phosphorylated at Tyr142 accumulates in the cell, which increases β-catenin transcriptional activity and the expression levels of the target genes of β-catenin/T-cell factor (a Wnt transcription factor) [
27]. Here, we provide solid evidence that
miR-199a-3p plays an important role in regulating hair follicle development by inducing PTyr142 β-catenin nuclear translocation.
As an important component of the Wnt-signaling pathway, β-catenin plays a critical role in hair follicle cycle development and hair follicle stem cell differentiation [
36]. The activation of β-catenin at the background level leads to the beginning of hair follicle morphogenesis in the adult skin, which is otherwise a specific phenomenon at the embryonic stage [
37]. Conversely, the specific inactivation of β-catenin transforms stem cells into epithelial cells rather than hair follicle cells [
38]. In β-catenin-overexpressing transgenic mice with amino-terminal truncation, the proliferation of hair follicle bulge region cells, volume of hair follicles, and cyclin-D expression were increased, whereas the number of labeled cells was decreased [
39].
In recent years, research has shown that the aberrant activation of the Wnt-signaling pathway is associated with the development and progression of alopecia areata [
40,
41]. Studies have found that the activity of the Wnt-signaling pathway is reduced in the hair follicles of patients with alopecia areata, causing disruption of the hair follicle growth cycle and ultimately resulting in hair loss [
42]. Similar results were obtained in our study with animal models, where the local intradermal injection of
miR-199a-3p antagomir led to a decrease in the Wnt signaling-pathway activity and the inhibition of hair follicle development at the injection site. Furthermore, the expression of β-catenin, as an indispensable component of the downstream transcription factor complex in the Wnt-signaling pathway, is significantly downregulated in the hair follicles of patients with alopecia areata [
43]. This downregulation leads to aberrant Wnt-signaling pathway activity, disrupting normal hair follicle development and hair growth cycle, ultimately resulting in hair loss [
44]. Further research suggested that the low expression of the β-catenin gene may be closely associated with immune system abnormalities and alterations in the function of hair follicle stem cells in patients with alopecia areata [
45]. In the present study, using both lamb and mouse models, the PTPRF/β-catenin axis was identified as the primary target pathway of
miR-199a-3p. The inhibition of β-catenin transcriptional activity mediated by
miR-199a-3p indeed exhibited alopecia features, including abnormal activation of the local immune system and restricted hair growth. Therefore, an in-depth investigation of the role of the β-catenin gene in alopecia areata can contribute to gaining a better understanding of the mechanistic basis of the disease and provide potential avenues for the development of novel therapeutic strategies.
4. Materials and Methods
4.1. Animal and Sample Collection
C57/BL mice in this study were obtained from the Shanghai Research Center for Model Organisms (Shanghai, China) and 6 female mice from two litters were selected for intracutaneous injection experiment. Eight Chinese Aohan Merino lambs (female) were used for intravenous injection. The skin tissues of mice and lambs were collected and divided into two parts. One was used for HE staining, immunohistochemistry, and in situ hybridization (ISH), and the other was placed in liquid nitrogen for subsequent RNA-seq, Q-pcr, and Western blot. The lamb blood was collected for the follow-up Q-pcr of miR-199a-3p.
4.2. Cell Culture and Histological Analysis
HEK293T cells were obtained from the Institute of Biochemistry and Cell Biology, Chinese Academy of Science, P. R. China. All cells were cultured in DMEM, plus 10% FBS and penicillin/streptomycin. Cells were maintained at 37 °C with 5% CO2. All reagents used for cell culture were purchased from Invitrogen/Gibco (Carlsbad, CA, USA). Skin samples from back of lambs and mice were embedded in O.C.T. tissue freezing medium (CM1900; Leica, Nussloch, Germany) and sectioned (9 μm thickness). Sections were stained with hematoxylin and eosin (H&E) (C0105S, Beyotime, Beijing, China).
4.3. Dual Luciferase Assay
HEK293T cells were used to validate miR-199a-3p target. Cells were seeded into 24-cell plates (Corning Incorporated, New York, NY, USA) and transfected 24 h later with Lipofectamine 2000 (L3287-1ML, Sigma–Aldrich, St. Louis, MO, USA). The miR-199a-3p was co-transfected with 150 ng of psicheck2-PTPRF-fragment and 50 pmol of miR-199a-3p mimics, or negative control mimics (Ribobio, Guangzhou, China). The fragments in psicheck2-PTPRF-fragment were designed and synthesized by Shanghai Generay Biotech Co., Ltd. (Generay Biotech Co, Shanghai, China) and constructed into the psiCheck2 vector. Forty-eight hours after transfection, firefly and renlilla luciferase activities were measured using the dual-luciferase reporter kit (E1910, Promega, Madison, WI, USA). Assays were repeated three times.
4.4. The Detection of Cell Viability
Cell viability was detected by CellTiter–Lumi assay Plus kit (C0068S, Beyotime, Beijing, China). The specific steps are as follows: (A) Using a 96-well plate detected by chemiluminescence detection; (B) Inoculating 100 μL cells in each well, and ensuring that the number of cells in each well is less than 100,000, and setting a culture medium hole without cells as a negative control. Cells were cultured according to the conventional method of the cell culture; (C) Preparation of detection reagent (thawing and freezing at room temperature, CellTiter–Lumi Plus luminescence detection reagent (C0065, Beyotime, China) was thawed at room temperature. According to the amount of 100 μL per well in 96-well plates, appropriate amount of CellTiter–Lumi fluorescence Plus, photoluminescence detection reagent was chosen and balanced to room temperature). (D) Cell viability test: withdraw the cell culture plate and balance at room temperature for 10 min. Then, 100 μL CellTiter–Lumi Plus photoluminescence detection reagent was added to each well of 96-well plate. Shake at room temperature for 2 min and incubate at room temperature (about 25 °C) for 10 min. Chemiluminescence detection (Infinite 200 Pro, Tecan, Switzerland) was performed by using a multi-function enzyme labeling instrument. The relative viability of the cells was calculated directly from the chemiluminescence readings.
4.5. RNA Extraction and Q-PCR
Total RNA was extracted from HEK293Tcells, lambs, and mice skin tissue using TRIzol reagent according to the manufacturer’s instructions (15596026, Invitrogen, Carlsbad, CA, USA). cDNA synthesis was performed with 1 μg of total RNA, following the protocol accompanying the FastQuant RT Kit (KR116, TIANGEN, Beijing, China). To detect the relative expression of c-MYC, Axsin, Cd44, Cdx1, Cyclind1, Fn1, and Mmp7 mRNA, real-time PCR was performed with the primers shown in
Table S1, using β-actin as the reference gene. Primers for c-MYC, Axsin, Cd44, Cdx1, Cyclind1, Fn1, Mmp7, and β-actin were synthesized by Sangon (Sangon, Shanghai, China). The reverse transcription of
miR-199a-3p and
U6 was conducted according to the experimental procedure of kit TaqManTM MicroRNA Revverse Transcription Kit (#4366596, Thermo Fisher Scientific, Waltham, MA, USA). Among them, every 15 μL of reverse transcription reaction system needs 10 ng of total RNA, and the reverse transcription reaction system includes 7 μL of Mastermix mixture (see kit instructions), 3 μL of 5 × RTprimer, and 5 μL of RNA samples. Q-pcr selected SYBR Green qPCR mix kit and was conducted in BioRadCF × 96 (BioRad, Hercules, CA, USA) quantitative instrument. Reaction procedure: pre-denatured (30 s) at 95 °C, denaturing (10 s) at 95 °C, annealing (30 s) at 60 °C, extension (30 s) at 72 °C, for 40 cycles. The repeats of three holes were set for each sample, and U6 was used as the internal reference. The relative expression between groups was calculated by 2
−ΔΔCT [
46]. SAS9.1 was used for statistical analysis, while
p < 0.05 was selected as the level of significance.
4.6. Total Protein Extraction
Total protein was extracted from the skin tissue of lambs, mice, and HEK293T cells with ice-cold RIPA lysis buffer containing PMSF (phenylmethylsulfonyl fluoride) (P0013B, Beyotimes, Beijing, China). Samples were centrifuged at 4 °C for 30 min at 12,000× g. Total protein concentration was measured using a Braford protein assay kit (PA102, Tiangen, Beijing, China).
4.7. Cell Membrane Protein Extraction
Cell membrane proteins were completed according to Membrane and Cytosol Protein Extraction Kit (P0033, Beyotime, Beijing, China). The extraction of cell membrane protein was divided into tissue and cell. HEK293T cell membrane protein extraction should first cultivate about 2000-50-illion cells, wash them with PBS, scrape off the cells with cell scrapers, and blow down the cells with a pipette. Centrifuge to collect cells, absorb the supernatant, leaving cells to precipitate, and set aside. A small number of cells were counted, and the remaining cells were precipitated by centrifugation at 4 °C and 600× g for 5 min. The supernatant was discarded, followed by centrifugation at 4 °C and 600× g for 1 min to precipitate the residual liquid on the wall of the centrifuge tube and further precipitate the cells, and there is an attempt to absorb the residual liquid. Add 1 mL of membrane protein extraction Reagent A with PMSF before using 2000-50-million cells, gently and fully suspend the cells, and place them in an ice bath for 10–15 min. To extract the membrane protein of skin tissue, extract roughly 100 mg of tissue and cut it into small tissue fragments as carefully as possible with scissors. Add 1 mL of PMSF membrane protein extraction Reagent A before use, gently suspend the tissue fragments, and place in the ice bath for 10–15 min. Transfer the cell suspension or tissue sample to an ice bath precooled glass homogenizer of appropriate size, homogenizing for about 30–50 times. About 2–3 microliters of cells or tissue homogenate were dropped on the cover slide and observed under the microscope. If 70–80% of the cells had no perinuclear halo (a shiny ring around the nuclei) and intact cell morphology, indicating that the cells had been fully broken, the next experiment would be conducted. Centrifuge at 4 °C, 700× g for 10 min, and carefully collect the supernatant into a new centrifuge tube. Do not touch the precipitate when absorbing the supernatant. The cell membrane fragments were precipitated by centrifugation at 4 °C and 14,000× g for 30 min. Try your best to suck up the supernatant and gently touch the precipitation, or even absorb a very small amount of precipitation. Add membrane protein extraction reagent B200 microliter (if necessary, can also be increased to 300 microliters), the highest speed of violent Vortex5 s re-suspension precipitation, in ice bath for 5–10 min. Repeat the previous steps of vortex and ice bath incubation 1–2 times to fully extract membrane proteins. Then, it wass centrifuged at 4 °C and 14,000× g for 5 min, and the supernatant was collected as cell membrane protein solution.
4.8. Nuclear Protein Extraction and Western Blot
Nuclear proteins were completed according to Nuclear and Cytoplasmic Protein Extraction Kit (P0033, Beyotime, Beijing, China). For HEK293T cells, wash them with PBS, scrape off the cells with a cell scraper, and blow them down with a pipette. Centrifuge to collect cells and attempt to absorb the supernatant, leaving cells to precipitate and set aside. (A) Two hundred microliters of cytoplasmic protein extraction reagent added with PMSF was added every 20 microliters of cell precipitation. (B) The highest speed and violent Vortex 5 s, the cell precipitation was completely suspended and dispersed. (C) Ice bath for 10–15 min. (D) Add cytoplasmic protein extraction reagent B10 microliter. (E) The highest-speed violent Vortex 5 s, ice bath 1 min. (F) The highest-speed and violent Vortex 5 s, centrifuge at 4 °C 12,000–16,000× g for 5 min. (G) For precipitation, completely absorb the residual supernatant and add 50 microliters of nuclear protein extraction reagent added with PMSF. (H) The highest speed and violent Vortex 15–30 s, the cell precipitation was completely suspended and dispersed. (I) It was then placed again in the ice bath every 1–2 min before high-speed violent Vortex 15–30 s, a total of 30 min. (J), 4 °C 12,000–16,000× g centrifugation for 10 min. (K) Immediately absorb the supernatant into a precooled plastic tube, that is, the extracted nuclear protein. For skin tissue samples, cut the tissue into pieces as small as possible. Mix the equivalent cytoplasmic protein extraction reagents A and B according to the proportion of 20:1. The tissue homogenate was prepared by adding PMSF to the final concentration of 1 mM. The tissue and tissue homogenate were mixed according to the proportion of 200 microliters of tissue homogenate per 60 mg and fully homogenized in the glass homogenizer. Homogenization should be conducted in an ice bath, or at 4 °C. After homogenizing, transfer the homogenate to a plastic centrifuge tube and place in an ice bath for 15 min. Centrifuge at 4 °C 1500× g for 5 min. In the next step, the nuclear protein of skin tissue can be obtained according to A–K.
Thirty micrograms of total protein, 10 μg of membrane protein, and 10 μg of nucleo protein were separated by SDS–PAGE and transferred to PVDF membranes (Millipore, Billerica, MA, USA). The membranes were probed with specific primary antibodies (sc-135969, anti-PTPRF, Santa Cruz, Hercules, CA, USA) anti-β-catenin (E247, Abcam, Boston Metro, MA, USA) anti-p-β-catenin, pTyr142 (bs-2063R, Bioss, Beijing, China), β-actin (AF2811, Beyotime, Beijing, China), Caveolin-1 (AF0087, Beyotime, Beijing, China), and Lamin B1 (AF1408, Beyotime, Beijing, China), as well as appropriate secondary antibodies anti-rabbit-HRP (A0208, Beyotime, Beijing China) and anti-mouse-HRP (A0192, Beyotime, Beijing China). The PTPRF, β-catenin, p-β-catenin(pTyr142), β-actin, Caveolin-1, and Lamin B1 primary antibodies were diluted to 1:2000, 1:2000, 1:1000, 1:3000, 1:2000, and 1:2000 before use, respectively. The secondary antibodies were diluted to 1:3000.
4.9. RNA-Seq
A total of 4 μg of RNA from each skin and cell sample were used as input material for RNA sample preparation. Ribosomal RNA was removed using the Epicentre Ribo-zero™ rRNA Removal Kit (Epicentre, Madison, WI, USA); the mRNA sequencing libraries were constructed using the NEBNext
® Ultra™Directional RNA Library Prep Kit for Illumina
® (NEB, Ipswich, MA, USA), according to the manufacturer’s instructions. The index codes were used to attribute the sequences to each sample. Clustering of the index-coded samples was performed on the cBot Cluster Generation system using the TruSeq PE Cluster Kit v3-cBot-HS (Illumina). Subsequently, the mRNA libraries were sequenced on the Illumina Hiseq 2000 platform. The clean reads were obtained from raw reads by removing poly-N regions, reads containing adapters, and low-quality reads (Trimmomatic) [
47]. The Q20, Q30, and GC contents of the clean reads were calculated. The human reference genome and annotation files were obtained from the human genome website (
Table S2). The mouse reference genome and annotation files were obtained from the mouse genome website (
Table S1). The reference genome index was constructed using Bowtie2, and clean paired-end reads were aligned to the reference genome using TopHat [
48]. The mapped reads of each sample were assembled using both Cufflinks and Scripture (beta2) with a reference-based approach [
49]. The transcripts were either predicted based on the coding potential by the Coding-Non-Coding-Index (CNCI) [
50], Coding Potential Calculator, 0.9-r2 (CPC) [
51], or Pfam Scan [
52], and the phylogenetic codon substitution frequency (PhyloCSF) [
53] and all four programs were filtered out. Subsequently, those without coding potential were designated as the candidate mRNA set. We used the PhyloFit [
54] program to compute phylogenetic models for conserved and non-conserved regions among species. The phastCons program was used in conjunction with the model and HMM transition parameters to compute a set of conservation scores for the mRNAs. The Cuffdiff algorithm was used to calculate the fragments per kilobase of exon per million fragments mapped (FPKMs) of mRNAs in each sample. The DESeq2 package was employed for the analysis of differential gene expression. Using a model based on the negative binomial distribution, the DEGs with an adjusted
p-value (
p-adjust < 0.05; Benjamini–Hochberg multiple test correction).
4.10. miRNA-Seq
Total RNA, including small RNA, was extracted by TRIZOL, and the quality of the extracted RNA was tested by NanoDrop2000. RNA integrity was identified by 1.5% agarose gel electrophoresis. One microgram of total RNA was obtained from each sample, and the TruSeq Small RNA Sample Prep Kits (Illumina, San Diego, CA, USA) was used to build a small RNA library. Then, Illumina Hiseq2000 was used for subsequent sequencing, as well as the Ovis genome website (
Table S1). The raw data was presented in FASTQ format by removing the adaptors. We selected clean read lengths greater than 18 nt as small RNAs. The DEGs with an
p-value (
p-adjust < 0.05; Benjamini–Hochberg multiple test correction) between coarse and fine wool lambs were identified.
4.11. Proteome
The lysis buffer (200 μL, it contains 4% SDS, 100 mM DTT, 150 mM Tris-HCl pH 8.0) was used in the suspended skin tissues. Quantification of lysate supernatant by BCA Protein Assay Kit (Bio-Rad, Hercules, CA, USA). Digestion of protein (200 μg for each sample) was performed according to the FASP procedure. The peptide concentration was determined with OD280 by Nanodrop device. Two hundred micrograms of each sample were obtained for protein digestion by the FASP procedure, and the peptide concentration was determined using the Nanodrop device. Peptides were labeled with TMT reagents according to the manufacturer’s instructions (Thermo Fisher Scientific, Waltham, MA, USA), and each aliquot was reacted with one tube of TMT reagent, respectively. Full MS resolutions were set to 120,000 at
m/
z 200, and the full MS AGC target was 300% with an injection time of 25 ms. Mass range was set to 350–1400. The raw data were processed in Proteome Discoverer 2.4 (Thermo Fisher Scientific, Waltham, MA, USA) and imported into MaxQuant software (version 1.6.0.16) for data interpretation and according to the database Uniprot_ OvisAries _23084_ UP000002356, the original data were searched (
Table S2).
Analysis of the proteome data was performed using Perseus software (version 1.6.1.3), Microsoft Excel (version 2021), and R statistical computing software (version 3.6.3). Differentially expressed proteins were screened using a ratio fold change of >1.20 or <0.83 with a
p value < 0.05 as the threshold. Expression data were grouped together according to protein level by hierarchical clustering. To annotate the sequences, information was extracted from UniProtKB. For functional enrichment analysis of DEPs, GO and signaling pathway analyses were performed using the online tool David (
https://david.ncifcrf.gov/, accessed on 8 February 2021) [
55,
56] and Metascape (
https://metascape.org/gp/index.html, accessed on 20 February 2021) [
57], using Fisher’s exact test and also FDR correction for multiple testing. Enriched GO and signaling pathways were nominally statistically significant at the
p < 0.05 level.
4.12. Immunohistochemical
Lamb skin tissues were fixed in 4% paraformaldehyde formalin in PBS at 4 °C overnight, embedded in paraffin, and sectioned at 6 μm. The following antibodies were used for immunostaining: anti-p-β-catenin, pTyr142, bs-2063R, Bioss, China, and HRP-labeled goat anti-rabbit IgG(H + L) (A0208, Beyotime, Beijing, China). The signal was detected using the DAB Horseradish Peroxidase Color Development Kit (P0202, Beyotime, Beijing, China), and the sections were stained with hematoxylin. Photographs were recorded using a microscope (RVL-100-G, ECHO, San Diego, CA, USA).
4.13. In Situ Hybridization
In situ hybridization lamb skin tissue samples were divided into three groups according to the type of miRNA probe (EXQON, Vedbaek, Denmark): miR-199a-3p group, scramble-miR group, and U6 group. The specific steps are as follows: Prepare longitudinal paraffin sections of skin tissue, the thickness of which requires 5 μm. Dry the slices, put them in a dry-baked dish, and bake them at 60 °C for 45 min. Then, soak the slices in Xylene I, II, and III, respectively, each time for 5 min. Soak in 100% ethanol twice, each time for 5 min. Soak 5 min in 70% ethanol, and soak in 50% alcohol for 5 min. This is the process of deproteinization (DPBS soaking twice, each time for 5 min, and treated with 10 μg/mL protease K at 37 °C every 5 min). Configure the protease buffer in advance and incubate it at 37 °C. Soak in 0.2% glycine (0.2 g glycine + 100 mL DPBS) for 30 s. Soak in DPBS twice for 30 s each time. Then, fix 4% paraformaldehyde for 10 min at room temperature. Soak DPBS twice, each time for 5 min. Pre-hybridization (putting the slice in a wet box, encircling the tissue in the section with a hydrophobic pen and dripping hybrid buffer; the composition of buffer includes 50% formamide 5 mL, 5 × SSC 2.5 mL, 0.1% Tweenly20 0.01 mL, 9.2 mM citric acid, 50 μg/mL heparin 10 μL, 500 μg/mL Yeast RNA 250 μL, DEPC water 1.230 mL). Implement pre-hybridization at 60 °C for 2 h, and then hybridization at 60 °C for 16 h (the concentration of probe solution is 25 μM, the concentration of working solution is 45 nM). If 300 μL probe solution was added to each sample, 0.54 μL probe + 300 μL pre-hybrid solution is required. Wash twice with 2 × SSC for 10 min each time (wash at hybrid temperature, 60 °C). Wash 3 times with 50% formamide at hybrid temperature of 60 °C, each time 30 min. Wash five times in DPBS, each time for 5 min. Blocking: seal at room temperature for 1 h. The first antibody reaction: the Dig labeled primary antibody (anti-DIG-AP) was diluted with the sealed liquid according to 1:2000, and the reaction was about 16 h overnight at 4 °C. DPBST (0.1% Tween) was washed 5 times, each time for 5 min. AP buffer washed 3 times, each time for 5 min. At room temperature, add NBT/BCIP (Roche, 11697471001, Basle, Swizerland); the duration does not exceed 48 h. Add 400 μL of chromogenic solution to each sample. PBST was washed 3 times, each time for 5 min. Dehydration: 70%, 80%, 95%, 100% (Alcohol gradient). Then, keep in Xylene I, II for 2 min. Neutral gum seal. Observe under a microscope and record pictures.
4.14. Intracutaneous Injection in Mice
First, 10 nmol miR-199a-3p agomir freeze-dried powder was diluted with 50 μL of RNase free water for intracutaneous injection in mice and cryopreserved every 5 μL. The freeze-dried powder of 50 nmol miR-199a-3p antagomir was diluted with 50 μL of RNase free water and frozen every 5 μL. The repackaging method of 10 nmol miR-199a-3p agomir negative control dry powder is the same as that of 10 nmol miR-199a-3p agomir, and 50 nmol miR-199a-3p antagomir negative control dry powder is the same as that of 50 nmol miR-199a-3p antagomir. Two litters of mice with the same sex (female) were selected: one litter selected 48-day-old mice (Telogen hair follicle); three mice were from the miR-199a-3p agomir group, and another three mice in the same litter were from the miR-199a-3p agomir control group. The second litter selected 42-day-old mice (Catagen hair follicle); three mice were from the miR-199a-3p antagomir group, while the other three mice were from the miR-199a-3p antagomir control group. Every 5 μL of miR-199a-3p agomir, miR-199a-3p agomir negative control, miR-199a-3p antagomir, and miR-199a-3p antagomir negative control cryopreservation solution were added with 95 μL of DPBS for each mouse injection. MiR-199a-3p agomir group injected miR-199a-3p agomir, miR-199a-3p agomir control group injected miR-199a-3p agomir negative control, miR-199a-3p antagomir group injected miR-199a-3p antagomir, and miR-199a-3p antagomir control group injected miR-199a-3p antagomir negative control once a day for 3 days.
4.15. Lamb Intravenous Injection
For Lamb intravenous injection experiment, 100 nmol of miR-199a-3p agomir and 100 nmol of miR-199a-3p agomir negative control were purchased from Guangzhou Ruibo Science and Technology Biotechnology Co., Ltd. (Ribobio, Guangzhou, China). The experimental group included four newborn merino lambs (injected miR-199a-3p agomir), and the control group included four newborn merino lambs (injected miR-199a-3p agomir negative control). These lambs are of the same sex (female). MiR-199a-3p agomir and miR-199a-3p agomir negative control were packaged into one tube per 20 nmol and diluted with 1.2 mL of 10% glucose solution, respectively. The lamb should be fixed in a more comfortable position. Standard procedures for jugular vein injection were employed to administer miR-199a-3p agomir and miR-199a-3p agomir negative control solution to the lambs. Each lamb was injected into the jugular vein three times a day, each time with 0.4 mL of diluted miR-199a-3p agomir and miR-199a-3p agomir negative control solution once every 3 h. The experimental group and the control group were photographed before, and 18 days after injection, and the wool was collected at 0 days, 1 day, 5 days, and 18 days after injection. The venous blood and skin tissue of lambs in the experimental group and control group were collected.
4.16. Statistical Analysis
All statistical details for the RNA-seq experiments can be found in the above sections. PCA and heatmap of the mRNA-seq data were performed using the R package (Version 4.2). Venn diagrams of DEGs and DEPs were performed using an online Venn diagram tool (
http://bioinformatics.psb.ugent.be/webtools/Venn/, accessed on 24 November 2022). Data were analyzed using two-tailed
t-tests with the following
p-values: *
p < 0.05; **
p < 0.01; ***
p < 0.001.